摘要:目的: 通过分析健康体检者心电图异常的发生率及类型,为当地人群心血管疾病的早期诊断、早期治疗提供依据。 方法 : 采用光电三道心电图机在体检者安静休息状态下以常规12道描记,时间在15秒左右。按3个年龄段对健康体检患者心电图进行分组分析,同时对心电图异常者做病因诊断。 结果 : 1356例完成十二导联心电图监测,异常心电图占2257%,其中STT异常占首位1123%。41～60岁人群心电图异常的检出率男性较高,且多伴高血压、血糖异常、血脂异常等; 61～81 岁组人群心电图异常的检出率最高,且多已存在糖尿病、高血压和冠状动脉供血不足等疾病。 结论 :定期进行心电图检查,对早期发现、预防、诊断心血管疾病有重要意义。Abstract: Objective: To provide evidences for the early diagnosis and treatment of cardiovascular diseases through the analysis of the electrocardiographic abnormality and category. Methods : Analyzing the health examination electrocardiogram according to age and etiological diagnosis were committing to cases with electrocardiographic abnormality. Results : 1356 cases finished the electrocardiography. The rate of electrocardiographic abnormality was 2257%, and the STT abnormality hold the first place (1123%). The rate of electrocardiographic abnormality increased with the increasing age and it is highest in the 61~81 ages. Conclusion : Regular health examination by electrocardiography is important for early diagnosis, prevention and treatment of potential cardiovascular disease.
Objective T o observe the efficacy and safety of intravitreal injection of ranibizumab (Lucentis) for 12 consecutive months treating exudative age-related macular degeneration (EAMD). Methods This is an open and prospective study without control trial. Twenty-two eyes from 22 patients (18 males and 4 females) with EAMD diagnosed by fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) were enrolled in this study. The patients aged from 46 to 79 years with the mean of 68.2plusmn;9.3 years. All of the patients received intravitreal injection of ranibizumab (0.5 mg, 0.05 ml) once a month for 12 consecutive months. The best-corrected visual acuity (BCVA) was obtained using the international standard visual acuity chart (converted into logMAR for statistical analysis). Central retinal thickness (CRT) was measured by optical coherence tomography (OCT) before and after each monthly treatment. Intraocular pressure (IOP) was measured using non-contact tonometry before treatment and 1 hour and 1 day after treatment. FFA and ICGA were performed every 3 months. The BCVA was 0.01 -0.9 with the average of 0.26plusmn;0.22. The average logMAR BCVA was 0.76plusmn;0.44, the CRT was 182-559 mu;m with the mean of (302.62plusmn;90.18) mu;m, and the IOP was normal before treatment. Only 13 of 22 patients completed 12 months of follow-up. The BCVA, CRT and IOP after treatment were compared with baseline using paired t test. Results Of all the 22 patients, the mean logMAR BCVA at 1 and 3 months after treatment were 0.52plusmn;0.32 and 0.37plusmn;0.27 respectively, both of which were significantly different compared with before treatment (t=4.518, 6.237;P＜0.05). Of the 13 patients, the mean logMAR BCVA at 1, 3 and 12 months after treatment was 0.51plusmn;0.34, 0.35plusmn;0.26, 0.34plusmn;0.30 respectively. All of these measures were significantly different compared with 0.74plusmn;0.37 before treatment (t=3.443, 5.438, 4.756;P＜0.05) . The mean CRT at 1, 3 and 12 months after treatment were (228.85plusmn;54.93), (231.00plusmn;38.94) and (262.92plusmn;70.48) mu;m. There were significant differences among before and 1, 3 months after treatment (t=2.914, 3.199;P＜0.05), but not between before and 12 months after treatment (t=1.408, P＞0.05). The first 3 injections contributed to the most BCVA gain with 6 patientsprime; BCVA increasing from 0.1- 0.5 to 0.5 or above. The greatest CRT reduction was obtained at 1 month after the first injection. IOP increased 1 hour after treatment and recovered within 1 day. No intravitreal injection-related side effects such as endophthalmitis were observed during the follow-up period. Conclusions Monthly intravitreal injections of ranibizumab may improve BCVA and macular edema. There was no adverse event during the follow-up duration.